In support of the potential for RAC1B to contribute to cetuximab resistance, BRAF(V600E) mutations commonly seen in CRC resistance to cetuximab generally induce senescence in CRC, but if colonocytes express BRAF(V600E) and have RAC1B overexpression, senescence markers are downregulated and cells have a growth advantage [40,133]. The gene discussed is BRAF; the disease is colorectal carcinoma.